High-risk pregnancy

Bectran Announces Cutting-Edge Advanced Fraud Prevention Suite for Enhanced Risk Management and Credit Decision Making

Retrieved on: 
Tuesday, August 8, 2023

Bectran, Inc. , a global leader in innovative, comprehensive B2B credit management solutions, proudly announces the launch of its revolutionary Advanced Fraud Prevention Suite.

Key Points: 
  • Bectran, Inc. , a global leader in innovative, comprehensive B2B credit management solutions, proudly announces the launch of its revolutionary Advanced Fraud Prevention Suite.
  • This groundbreaking suite of risk mitigation services is designed to empower businesses with robust fraud detection capabilities through comprehensive, adaptable risk models for enhanced decision making, online presence evaluation and customizable risk thresholds for unparalleled risk management and credit decision making.
  • Bectran’s Advanced Fraud Prevention Suite contains key features, including the following, to create a comprehensive, overall risk score that better predicts the risk an applicant presents.
  • The Advanced Fraud Prevention Suite is one of many service offerings from Bectran and can be implemented into any business profile immediately.

Atea Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Monday, August 8, 2022

New antivirals with improved profiles are urgently needed, said Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea Pharmaceuticals.

Key Points: 
  • New antivirals with improved profiles are urgently needed, said Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea Pharmaceuticals.
  • For dengue, we are currently enrolling two proof-of-concept trials for AT-752 and expect initial results in late 2022.
  • Operational planning for this trial is currently underway with the goal of initiation during the fourth quarter of 2022.
  • Results from the human challenge trial and initial results from the DEFEND-2 study are expected in the fourth quarter of 2022.

Bio-Path Holdings Reports Full Year 2021 Financial Results

Retrieved on: 
Friday, March 11, 2022

We continued to make steady progress throughout 2021 in pursuit of our mission to bring innovative therapies to the fight against cancer.

Key Points: 
  • We continued to make steady progress throughout 2021 in pursuit of our mission to bring innovative therapies to the fight against cancer.
  • Presented Data from Ongoing Phase 2 Study of Prexigebersen at 2021 American Society of Hematology Annual Meeting.
  • As of December 31, 2021, the Company had cash of $23.8 million, compared to $13.8 million at December 31, 2020.
  • ET to review these full-year 2021 financial results and to provide a general update on the Company.

Medtronic study shows patients with high blood pressure are interested in an interventional procedure treatment option

Retrieved on: 
Thursday, November 4, 2021

DUBLIN and ORLANDO, Fla., Nov. 4, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced findings from a new study of the Patient Preferences for the Treatment of Hypertension. The findings will be presented later today during the "What's Novel in Interventional Hypertension session" at the 33rd Transcatheter Cardiovascular Therapeutics (TCT 2021) conference, the annual scientific symposium of the Cardiovascular Research Foundation.

Key Points: 
  • The study found that in exchange for treatment risks, patients on average would require a minimal acceptable benefit of less than 2.5mmHg reduction in office-based systolic blood pressure.
  • These findings suggest that despite the risks of an intervention, patients may accept lower blood pressure reductions than those observed in published literature of Medtronic Symplicity Spyral Renal Denervation procedure1,2.
  • The study also concluded that blood pressure reduction was the most important driver of patient preference over all other attributes like medication burden and treatment (including interventional treatment-related) risks.
  • 24.3% of patients would be willing to consider an interventional approach such as RDN with reductions in office blood pressure anticipated at 5 mmHg.

March of Dimes and CDC Share Tips to Help Women Plan for a Healthy Pregnancy and Baby in the New Year

Retrieved on: 
Tuesday, December 15, 2020

As we face the COVID-19 pandemic, pregnant women must take special care of themselves as they prepare for their baby.

Key Points: 
  • As we face the COVID-19 pandemic, pregnant women must take special care of themselves as they prepare for their baby.
  • Even though all births defects can't be prevented, there are things women can do to help have a healthy baby.
  • You can adopt behaviors to increase your chances of having a healthy, full-term pregnancy and baby.
  • Creating a treatment plan for your health condition before you are pregnant can help keep you and your developing baby healthy.

Heart Attack Risk on the Rise for Pregnant Women and Death Rate Remains High

Retrieved on: 
Wednesday, July 18, 2018

As published online July 18 in the Mayo Clinic Proceedings, the study, led by NYU School of Medicine researchers, found that the risk of suffering a heart attack among pregnant women rose 25 percent from 2002 to 2014.

Key Points: 
  • As published online July 18 in the Mayo Clinic Proceedings, the study, led by NYU School of Medicine researchers, found that the risk of suffering a heart attack among pregnant women rose 25 percent from 2002 to 2014.
  • The researchers suggest that the trend among many women to have children later in life is one possible reason for the increase, as heart attack risk rises with age overall, and especially during pregnancy.
  • More women, they say, are also obese and/or have diabetes, key risk factors for heart attack.
  • The study also provided further evidence that the risk of having a heart attack during pregnancy rises as women get older.